Retrospective Analysis of the Effects of Enzymotec's Vayarin(R) Showed Significant Improvement of Emotional Status and Sleep ...
November 09 2015 - 9:00AM
Enzymotec Ltd. (Nasdaq:ENZY) ("Enyzmotec" or the "Company"), a
developer, manufacturer and marketer of innovative bio-active
lipid-based nutritional ingredients and medical foods, today
announced that a poster entitled "ANALYZING THE EFFECT OF VAYARIN®
ON EMOTIONAL REGULATION AND SLEEP QUALITY IN ADHD PATIENTS
SUFFERING FROM SLEEP DISTURBANCES" was presented at the American
Academy of Child and Adolescent Psychiatry's (AACAP) 62nd annual
meeting by Dr. Arnold Mech, Medical Director and Head of The Mech
Center Outpatient and Research, Sleep Centers of Texas. The poster
presentation outlined the results of a retrospective analysis that
evaluated the effect of Vayarin® on emotional regulation and sleep
quality in ADHD patients suffering from sleep disturbances.
Vayarin®, a unique prescription-based medical food that
addresses lipid imbalances associated with ADHD, has been
demonstrated to significantly reduce ADHD symptoms, especially in
children with emotional dysregulation. Additionally, Vayarin® has
been clinically shown to be safe and well-tolerated in
children.
In the present analysis, the effect of Vayarin® was
retrospectively evaluated in patients with ADHD, who also suffered
from sleep disturbances, identified through patient electronic
health records (EHR). A self-assessed emotional dysregulation
inventory (MEDI-Mech), as well as Polysomnography (PSG) and the
Fatigue Assessment Scale (FAS), were used to assess the effect of
Vayarin® on emotional dysregulation and sleep quality.
Results showed that Vayarin® significantly improved emotional
status and quality of sleep, as demonstrated by a significant
increase in Rapid Eye Movement (REM). In addition, the majority of
participants reported an improvement in fatigue symptoms.
Rob Crim, VAYA Pharma's Chief Executive Officer, commented, "We
are pleased by the results of this retrospective study on Vayarin.
We look forward to continuing to be able to demonstrate the
positive effects in ADHD patients."
About VAYA Pharma
VAYA Pharma is a specialty pharmaceutical division of Enzymotec
Ltd. dedicated to the discovery, development, manufacture and
marketing of innovative lipid-based compositions familiar to the
human body for addressing disorders that are impacted by lipid
imbalances.
VAYA Pharma's medical food portfolio addresses three therapeutic
segments: ADHD (Vayarin®), Early Memory Impairment (Vayacog®) and
Hypertriglyceridemia (Vayarol®). VAYA Pharma products are available
in the U.S. only by prescription under the supervision of a
physician. VAYA Pharma USA is headquartered in Baltimore, Maryland.
For more information, visit www.vayapharma.com and
www.vayarin.com.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures, and
markets innovative bio-active lipid based nutritional ingredients
and medical foods, driven by a deep core of cutting-edge,
proprietary technologies intended to improve people's health. For
more information, visit www.enzymotec.com.
CONTACT: The Ruth Group
Tram Bui/Lee Roth
#646-536-7035/7012
tbui@theruthrgoup.com
lroth@theruthgroup.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024